Skip to main content
SpringerLink
Log in

Drug Therapy Optimization at the End of Life

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Older people reaching end-of-life status are particularly at risk of adverse effects of drug therapy. Polypharmacy, declining organ function, comorbidity, malnutrition, cachexia and changes in body composition all sum up to increase the risk of many drug-related problems in individuals who receive end-of-life care.

End of life is defined by a limited lifespan or advanced disability. Optimal prescribing for end-of-life patients with multimorbidity, especially in those dying from non-cancer conditions, remains mostly unexplored, despite the increasing recognition that the management goals for patients with chronic diseases should be redefined in the setting of reduced life expectancy. Most drugs used for symptom palliation in end-of-life care of older patients are used without solid evidence of their benefits and risks in this particularly frail population. Appropriate dosing or optimal administration routes are in most cases unknown.

Avoiding or discontinuing drugs that aim to prolong life or prevent disability is usually common sense in end-of-life care, particularly when the time needed to obtain the expected benefits from the drug is longer than the life expectancy of a particular individual. However, discontinuation of drugs is not standard practice, and prescriptions are usually not adapted to changes in the course of advanced diseases. Careful consideration of remaining life expectancy, time until benefit, goals of care and treatment targets for each drug seems to be a sensible framework for decision making.

In this article, some key issues on drug therapy at the end of life are discussed, including principles of decision making about drug treatments, specific aspects of drug therapy in some common geriatric conditions (heart failure and dementia), treatment of acute concurrent problems such as infections, evidence to guide the choice and use of drugs to treat symptoms in palliative care, and avoidance of some long-term therapies in end-of-life care.

Solid evidence is lacking to guide optimal pharmacotherapy in most end-of-life settings, especially in non-cancer diseases and very old patients. Some open questions for research are suggested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Pautex S, Curiale V, Pfisterer M, et al. A common definition of geriatric palliative medicine. J Am Geriatr Soc 2010; 58 (4): 790–1

    Article  PubMed  Google Scholar 

  2. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011; 171 (6): 550–6

    Article  PubMed  Google Scholar 

  3. Curiale V. World-wide literature survey on geriatric palliative medicine. Eur Geriatr Med 2011; 2 (1): 6–11

    Article  Google Scholar 

  4. van der Steen JT, Heymans MW, Steyerberg EW, et al. The difficulty of predicting mortality in nursing home residents. Eur Geriatr Med 2011; 2 (2): 79–81

    Article  Google Scholar 

  5. O’Mahony D, O’Connor MN. Pharmacotherapy at the end-of-life. Age Ageing 2011; 40 (4): 419–22

    Article  PubMed  Google Scholar 

  6. Lee SP, Bain KT, Maio V. Appropriate discontinuation of medications at the end of life: a need to establish consensus criteria. Am J Med Qual 2007; 22 (6): 393–4

    Article  PubMed  Google Scholar 

  7. Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166 (6): 605–9

    Article  PubMed  Google Scholar 

  8. Currow DC, Stevenson JP, Abernethy AP, et al. Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007; 55 (4): 590–5

    Article  PubMed  Google Scholar 

  9. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000; 18 (8): 1780–99

    PubMed  CAS  Google Scholar 

  10. Moorman SM. Older adults’ preferences for independent or delegated end-of-life medical decision making. J Aging Health 2011; 23 (1): 135–57

    Article  PubMed  Google Scholar 

  11. Freeman SL, Berger AM. Nebraska veterans’ preferences for end-of-life care. Clin J Oncol Nurs 2009; 13 (4): 399–403

    Article  PubMed  Google Scholar 

  12. Clarke A, Seymour J. ‘At the foot of a very long ladder’: discussing the end of life with older people and informal caregivers. J Pain Symptom Manage 2010; 40 (6): 857–69

    Article  PubMed  Google Scholar 

  13. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: ‘there’s got to be a happy medium’. JAMA 2010; 304 (14): 1592–601

    Article  PubMed  CAS  Google Scholar 

  14. Costanzo MR, Mills RM, Wynne J. Characteristics of ‘stage D’ heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). Am Heart J 2008; 155 (2): 339–47

    Article  PubMed  Google Scholar 

  15. Martin-Pfitzenmeyer I, Gauthier S, Bailly M, et al. Prognostic factors in stage D heart failure in the very elderly. Gerontology 2009; 55 (6): 719–26

    Article  PubMed  Google Scholar 

  16. Goodlin SJ. End-of-life care in heart failure. Curr Cardiol Rep 2009; 11 (3): 184–91

    Article  PubMed  Google Scholar 

  17. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009; 30 (4): 478–86

    Article  PubMed  Google Scholar 

  18. Lewis EF. End of life care in advanced heart failure. Curr Treat Options Cardiovasc Med 2011; 13 (1): 79–89

    Article  PubMed  Google Scholar 

  19. Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001; 20 (9): 1016–24

    Article  PubMed  CAS  Google Scholar 

  20. Janssen DJ, Spruit MA, Wouters EF, et al. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med 2008; 22 (8): 938–48

    Article  PubMed  CAS  Google Scholar 

  21. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000; 48 (5 Suppl.): S101–9

    PubMed  CAS  Google Scholar 

  22. Schoevaerdts D, Swine C, Vanpee D. Heart failure. N Engl J Med 2003; 349 (10): 1002–4

    Article  PubMed  Google Scholar 

  23. Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol 2009; 54 (5): 386–96

    Article  PubMed  Google Scholar 

  24. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11 (5): 433–43

    Article  PubMed  Google Scholar 

  25. McKelvie RS, Moe GW, Cheung A, et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011; 27 (3): 319–38

    Article  PubMed  Google Scholar 

  26. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27 (19): 2338–45

    Article  PubMed  CAS  Google Scholar 

  27. Wong M, Staszewsky L, Carretta E, et al. Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT. Eur J Heart Fail 2006; 8 (5): 502–8

    Article  PubMed  Google Scholar 

  28. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106 (17): 2194–9

    Article  PubMed  Google Scholar 

  29. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709–17

    CAS  Google Scholar 

  30. Toma M, Starling RC. Inotropic therapy for end-stage heart failure patients. Curr Treat Options Cardiovasc Med 2010; 12 (5): 409–19

    Article  PubMed  Google Scholar 

  31. Licata G, Di PP, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 2003; 145 (3): 459–66

    Article  PubMed  CAS  Google Scholar 

  32. Frea S, Franco E, Najd K, et al. Refractory acute decompensated heart failure: an observational study on a non-invasive hemodynamic monitoring system aimed at improving the therapeutic approach. J Cardiovasc Med (Hagerstown) 2010; 11 (9): 655–61

    Article  Google Scholar 

  33. Parsons C, Hughes CM, Passmore AP, et al. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the dis-advantaged dying? Drugs Aging 2010; 27 (6): 435–49

    Article  PubMed  Google Scholar 

  34. Rexach L. Palliative care in dementia. Eur Geriatr Med 2012; 3: 131–40

    Article  Google Scholar 

  35. Chan VT, Woo BK, Sewell DD, et al. Reduction of sub-optimal prescribing and clinical outcome for dementia patients in a senior behavioral health inpatient unit. Int Psychogeriatr 2009; 21 (1): 195–9

    Article  PubMed  Google Scholar 

  36. Bain KT, Holmes HM, Beers MH, et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc 2008; 56 (10): 1946–52

    Article  PubMed  Google Scholar 

  37. Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin 2009; 25 (11): 2577–87

    PubMed  CAS  Google Scholar 

  38. Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009; 8 (1): 39–47

    Article  PubMed  CAS  Google Scholar 

  39. Seltzer B. Is long-term treatment of Alzheimer’s disease with cholinesterase inhibitor therapy justified? Drugs Aging 2007; 24 (11): 881–90

    Article  PubMed  CAS  Google Scholar 

  40. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007; 55 (10): 1517–23

    Article  PubMed  Google Scholar 

  41. Weschules DJ, Maxwell TL, Shega JW. Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. J Palliat Med 2008; 11 (5): 738–45

    Article  PubMed  Google Scholar 

  42. Daiello LA, Ott BR, Lapane KL, et al. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 2009; 7 (2): 74–83

    Article  PubMed  CAS  Google Scholar 

  43. Shega JW, Ellner L, Lau DT, et al. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med 2009; 12 (9): 779–83

    Article  PubMed  Google Scholar 

  44. Kverno KS, Rabins PV, Blass DM, et al. Prevalence and treatment of neuropsychiatric symptoms in advanced dementia. J Gerontol Nurs 2008; 34 (12): 8–15

    Article  PubMed  Google Scholar 

  45. Blass DM, Black BS, Phillips H, et al. Medication use in nursing home residents with advanced dementia. Int J Geriatr Psychiatry 2008; 23 (5): 490–6

    Article  PubMed  Google Scholar 

  46. Arinzon Z, Peisakh A, Schrire S, et al. Delirium in long-term care setting: indicator to severe morbidity. Arch Gerontol Geriatr 2011; 52 (3): 270–5

    Article  PubMed  Google Scholar 

  47. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8 (2): 151–7

    Article  PubMed  CAS  Google Scholar 

  48. Agar M, Draper B, Phillips PA, et al. Making decisions about delirium: a qualitative comparison of decision making between nurses working in palliative care, aged care, aged care psychiatry, and oncology. Palliat Med. Epub 2011 Sep 9

  49. Leonard M, Agar M, Mason C, et al. Delirium issues in palliative care settings. J Psychosom Res 2008; 65 (3): 289–98

    Article  PubMed  Google Scholar 

  50. Gagnon PR. Treatment of delirium in supportive and palliative care. Curr Opin Support Palliat Care 2008; 2 (1): 60–6

    Article  PubMed  Google Scholar 

  51. Laredo L, Vargas E, Blasco AJ, et al. Risk of cerebrovas- cular accident associated with use of antipsychotics: population-based case-control study. J Am Geriatr Soc 2011; 59 (7): 1182–7

    Article  PubMed  Google Scholar 

  52. Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf 2010; 33 (4): 273–88

    Article  PubMed  CAS  Google Scholar 

  53. Pratt NL, Roughead EE, Ramsay E, et al. Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series. Drugs Aging 2010; 27 (11): 885–93

    Article  PubMed  Google Scholar 

  54. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 2006; 54 (2): 354–61

    Article  PubMed  Google Scholar 

  55. Azermai M, Elseviers M, Petrovic M, et al. Assessment of antipsychotic prescribing in Belgian nursing homes. Int Psychogeriatr 2011; 23 (8): 1240–8

    Article  PubMed  Google Scholar 

  56. Osler W. Principles and practice of medicine designed for the use of practitioners and students of medicine. 3rd ed. London: Young J. Pentland, 1898: 108–37

    Google Scholar 

  57. van der Steen JT, Pasman HR, Ribbe MW, et al. Discomfort in dementia patients dying from pneumonia and its relief by antibiotics. Scand J Infect Dis 2009; 41 (2): 143–51

    Article  Google Scholar 

  58. Givens JL, Jones RN, Shaffer ML, et al. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 2010; 170 (13): 1102–7

    Article  PubMed  Google Scholar 

  59. D’Agata E, Mitchell SL. Patterns of antimicrobial use among nursing home residents with advanced dementia. Arch Intern Med 2008; 168 (4): 357–62

    Article  PubMed  Google Scholar 

  60. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis 2004; 4 (2): 112–24

    Article  PubMed  Google Scholar 

  61. Stiel S, Krumm N, Pestinger M, et al. Antibiotics in palliative medicine-results from a prospective epidemiological investigation from the HOPE survey. Support Care Cancer 2012; 20 (2): 325–33

    Article  PubMed  Google Scholar 

  62. Kongsgaard UE, Werner MU. Evidence-based medicine works best when there is evidence: challenges in palliative medicine when randomized controlled trials are not possible. J Pain Palliat Care Pharmacother 2009; 23 (1): 48–50

    Article  PubMed  Google Scholar 

  63. Miller SC, Mor V, Wu N, et al. Does receipt of hospice care in nursing homes improve the management of pain at the end of life? J Am Geriatr Soc 2002; 50 (3): 507–15

    Article  PubMed  Google Scholar 

  64. Dalacorte RR, Rigo JC, Dalacorte A. Pain management in the elderly at the end of life. N Am J Med Sci 2011; 3 (8): 348–54

    Article  PubMed  Google Scholar 

  65. Wiffen PJ, Edwards JE, Barden J, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev 2003; (4): CD003868

    PubMed  Google Scholar 

  66. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006; (1): CD004311

    PubMed  Google Scholar 

  67. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006; 174 (11): 1589–94

    PubMed  Google Scholar 

  68. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8 (4): 287–313

    Article  PubMed  Google Scholar 

  69. American Geriatrics Society. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57 (8): 1331–46

    Article  Google Scholar 

  70. King S, Forbes K, Hanks GW, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011; 25 (5): 525–52

    Article  PubMed  CAS  Google Scholar 

  71. Strasser F, Walker P, Bruera E. Palliative pain management: when both pain and suffering hurt. J Palliat Care 2005; 21 (2): 69–79

    PubMed  Google Scholar 

  72. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31 (1): 58–69

    Article  PubMed  Google Scholar 

  73. Ben-Aharon I, Gafter-Gvili A, Paul M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008; 26 (14): 2396–404

    Article  PubMed  Google Scholar 

  74. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010; (1): CD007354

    PubMed  Google Scholar 

  75. Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev 2008; (3): CD004769

    PubMed  Google Scholar 

  76. Zacharias H, Raw J, Nunn A, et al. Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure? Palliat Med 2011; 25 (6): 658–63

    Article  PubMed  Google Scholar 

  77. Hochgerner M, Fruhwald FM, Strohscheer I. Opioids for symptomatic therapy of dyspnoea in patients with advanced chronic heart failure: is there evidence? Wien Med Wochenschr 2009; 159 (23–24): 577–82

    Article  PubMed  Google Scholar 

  78. Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008; (2): CD005623

    PubMed  Google Scholar 

  79. Peuckmann V, Elsner F, Krumm N, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2010; (11): CD006788

    PubMed  Google Scholar 

  80. Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients: an EAPC approach. Palliat Med 2008; 22 (1): 13–32

    Article  PubMed  Google Scholar 

  81. Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer 2009; 17 (6): 745–8

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No funding was received for the preparation of this paper. The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Servicio de Geriatría, Hospital Universitario Ramón y Cajal, Ctra. Colmenar, km 9,1, 28034, Madrid, Spain

    Alfonso J. Cruz-Jentoft

  2. Geriatric Medicine, UC Louvain, St-Luc University Hospital, Brussels, Belgium

    Benoit Boland

  3. Unidad de Cuidados Paliativos, Hospital Universitario Ramón y Cajal, Madrid, Spain

    Lourdes Rexach

Authors
  1. Alfonso J. Cruz-Jentoft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benoit Boland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lourdes Rexach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alfonso J. Cruz-Jentoft.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cruz-Jentoft, A.J., Boland, B. & Rexach, L. Drug Therapy Optimization at the End of Life. Drugs Aging 29, 511–521 (2012). https://doi.org/10.2165/11631740-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11631740-000000000-00000

Keywords

Search

Navigation